कंपनी का अवलोकन
BiomX Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to the development of phage-based therapies utilizing natural and engineered technologies to target and eliminate specific harmful bacteria linked to chronic diseases. The firm functions within the broader Healthcare sector and the specialized Biotechnology industry, where innovation in microbial treatment represents a significant frontier for medical intervention. As of the latest available data, the company holds a market capitalization of $7.36M and maintains an operational workforce of 20 employees. These valuation and headcount figures indicate that BiomX Inc. is a small-cap entity with a limited revenue base, reflecting its early-stage nature where capital allocation focuses primarily on research and development rather than established commercial sales streams. The absence of substantial revenue relative to its market cap suggests the company is still in the phase of transforming scientific breakthroughs into marketable products, a characteristic common among pre-revenue biotechnology firms that rely heavily on external financing to sustain operations.
वित्तीय स्वास्थ्य
BiomX Inc. reports a Net Income of $-36,199,000 over the trailing twelve months, while EBITDA stands at $-27,998,000, highlighting a significant gap between operating earnings and bottom-line results. This discrepancy reveals a cost structure burdened by substantial non-operating expenses or interest costs that erode the company's operational profitability before reaching net income. The firm generates a Free Cash Flow of $-14,071,500, indicating a consistent outflow of cash that constrains financial flexibility and necessitates regular access to capital markets or existing reserves. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial scale or that its current revenue, if any, is insufficient to cover the direct costs of goods sold and operating expenses. The company holds $4.36M in cash against $1.44M in debt, resulting in a Debt to Equity ratio that is effectively N/A due to the absence of equity or specific debt metrics provided in standard formats, though the absolute debt level appears manageable relative to cash reserves. However, the Current Ratio stands at 0.87, signaling that current liabilities exceed current assets and suggesting potential short-term liquidity pressures that could impact the company's ability to meet obligations without further financing. Furthermore, the Return on Equity is -316.9% and the Return on Assets is -78.9%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently due to the company's deep losses and lack of profitable operations.
मूल्यांकन आकलन
The P/E Ratio (TTM) is N/A due to the absence of earnings, while the Forward P/E is listed as -0.36, a metric that typically appears in negative form for companies with negative earnings and suggests the market is pricing in future profitability expectations rather than current performance. The Price to Book ratio is -0.37, indicating a negative book value relative to market price, which often reflects a market perception of significant asset impairment or liabilities exceeding tangible assets in the valuation model. The Price to Sales ratio is N/A, and the EV/EBITDA stands at -0.82, suggesting that traditional valuation multiples are not applicable given the negative earnings and lack of sales data. The stock has experienced a wide trading range with a 52-Week High of $14.71 and a 52-Week Low of $1.50, placing the current valuation context within a broad spectrum of market sentiment volatility. The Beta value is 1.70, which implies that the stock exhibits significantly higher price volatility relative to the broader market, moving 70% more than the benchmark index during periods of market fluctuation. These valuation metrics collectively paint a picture of a high-risk, high-volatility instrument where standard financial comparables are distorted by the company's pre-profitability status and speculative nature.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, as the company has not generated sufficient revenue history to calculate year-over-year expansion rates, making comparisons to revenue growth impossible at this stage. Since the company is not a dividend payer, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that all available cash flow is retained within the company to fund ongoing research, development, and operational expenses rather than being distributed to shareholders. The absence of a dividend policy is consistent with the company's lifecycle stage, where reinvesting earnings into the phage-based therapy pipeline is prioritized over income generation for investors. Consequently, the overall growth and income profile is characterized by zero current income and undefined historical growth rates, relying entirely on the potential for future commercialization to drive shareholder value.